These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 1978492)
1. Drug interaction studies with remoxipride. Yisak W; von Bahr C; Farde L; Grind M; Mattila M; Ogenstad S Acta Psychiatr Scand Suppl; 1990; 358():58-62. PubMed ID: 1978492 [TBL] [Abstract][Full Text] [Related]
2. Interaction study between remoxipride and biperiden. Yisak W; Farde L; von Bahr C; Nilsson LB; Fredriksson G; Ogenstad S Psychopharmacology (Berl); 1993; 111(1):27-32. PubMed ID: 7870930 [TBL] [Abstract][Full Text] [Related]
3. Effects of remoxipride on psychomotor performance, alone and in combination with ethanol and diazepam. Mattila MJ; Mattila ME Acta Psychiatr Scand Suppl; 1990; 358():54-5. PubMed ID: 1978490 [TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of remoxipride. von Bahr C; Movin G; Yisak WA; Jostell KG; Widman M Acta Psychiatr Scand Suppl; 1990; 358():41-4. PubMed ID: 1978486 [TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers. von Bahr C; Wiesel FA; Movin G; Eneroth P; Jansson P; Nilsson L; Ogenstad S Psychopharmacology (Berl); 1991; 103(4):443-8. PubMed ID: 1676524 [TBL] [Abstract][Full Text] [Related]
6. Remoxipride--a new potential antipsychotic drug. Pharmacological effects and pharmacokinetics following repeated oral administration in male volunteers. Farde L; Grind M; Nilsson MI; Ogenstad S; Sedvall G Psychopharmacology (Berl); 1988; 95(2):157-61. PubMed ID: 2901121 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. Widerlöv E; Andersson U; von Bahr C; Nilsson MI Psychopharmacology (Berl); 1991; 103(1):46-9. PubMed ID: 1672458 [TBL] [Abstract][Full Text] [Related]
8. Remoxipride: pharmacokinetics and effect on plasma prolactin. Movin-Osswald G; Hammarlund-Udenaes M Br J Clin Pharmacol; 1991 Sep; 32(3):355-60. PubMed ID: 1685665 [TBL] [Abstract][Full Text] [Related]
9. Remoxipride--a new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers. Grind M; Nilsson MI; Nilsson L; Oxenstierna G; Sedvall G; Wahlén A Psychopharmacology (Berl); 1989; 98(3):304-9. PubMed ID: 2568653 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of an oral controlled release formulation of remoxipride: a double-blind, crossover comparison with conventional formulation in chronic schizophrenics. Soni SD; Tench D; Ashwood TJ; Movin G Acta Psychiatr Scand Suppl; 1990; 358():45-7. PubMed ID: 1978487 [TBL] [Abstract][Full Text] [Related]
11. Steady-state pharmacokinetics of controlled release and immediate release formulations of remoxipride in patients with chronic schizophrenia. Tench D; Soni SD; Ashwood T; Movin G Psychopharmacology (Berl); 1990; 101(1):132-6. PubMed ID: 1971445 [TBL] [Abstract][Full Text] [Related]
12. Effect of urinary pH on the plasma and urinary kinetics of remoxipride in man. Widerlöv E; Termander B; Nilsson MI Eur J Clin Pharmacol; 1989; 37(4):359-63. PubMed ID: 2574673 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of remoxipride controlled release and immediate release capsules in schizophrenic patients. Widerlöv E; Franzén G; Jansson P; Movin G Int Clin Psychopharmacol; 1990 Apr; 5(2):125-34. PubMed ID: 1974271 [TBL] [Abstract][Full Text] [Related]
14. Plasma concentration of remoxipride in relation to antipsychotic effect and adverse symptoms. The Canadian Remoxipride Study Group. Jostell KG; Lapierre YD Acta Psychiatr Scand Suppl; 1990; 358():48-50. PubMed ID: 1978488 [TBL] [Abstract][Full Text] [Related]
15. Tolerability and pharmacokinetics of remoxipride after intramuscular administration. Kahn JP; Yisak W; Albaret C; Nilsson L; Zaar-Hedin A; Laxenaire M Acta Psychiatr Scand Suppl; 1990; 358():51-3. PubMed ID: 1978489 [TBL] [Abstract][Full Text] [Related]
16. Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium. Chen G; Nomikos GG; Affinito J; Zhao Z Clin Pharmacokinet; 2016 Sep; 55(9):1115-27. PubMed ID: 27048210 [TBL] [Abstract][Full Text] [Related]
17. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia. Wadworth AN; Heel RC Drugs; 1990 Dec; 40(6):863-79. PubMed ID: 1981869 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of remoxipride in elderly psychotic patients. Movin G; Gustafson L; Franzén G; Widerlöv E; Soni SD; Tench D; Nilsson L; Yisak W Acta Psychiatr Scand Suppl; 1990; 358():176-80. PubMed ID: 1978480 [TBL] [Abstract][Full Text] [Related]
19. Effects of remoxipride on measures of psychological performance in healthy volunteers. Fagan D; Scott DB; Mitchell M; Tiplady B Psychopharmacology (Berl); 1991; 105(2):225-9. PubMed ID: 1686656 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic interactions among haloperidol, carteolol hydrochloride and biperiden hydrochloride. Isawa S; Murasaki M; Miura S; Yoshioka M; Uchiumi M; Kumagai Y; Aoki S; Hisazumi H; Kudo S Nihon Shinkei Seishin Yakurigaku Zasshi; 1999 Jul; 19(3):111-8. PubMed ID: 10495985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]